Integrated treatment of schizophrenia

A. C. Altamura, A. Fagiolini, S. Galderisi, P. Rocca, A. Rossi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Psychosocial therapies play an important role in the treatment of schizophrenia. These therapies are aimed at improving the functioning of the patient in the community, which in turn can lead to clinical improvement, such as reduction in the number of relapses or hospitalizations. Substantial evidence supports the use of many psychosocial therapies in schizophrenia, including cognitive behavioral therapy, assertive community treatment, cognitive remediation and functional skills training. The customization of pharmacological therapy in schizophrenia, besides the experience of the clinician and individual preferences of the patient, should be based on three sets of objective data: 1) clinical predictors of response to therapy; 2) predictable side effects of therapy; 3) pharmacogenetic and pharmacogenomic data. It has been made a considerable effort to improve adherence to antipsychotic treatment through the development of drugs with better tolerability, in formulations that enable long-term administration of the drug, including injectable long-acting (depot) antipsychotics. In recent years the development of these formulations of atypical antipsychotics and the promising results obtained in clinical trials are changing the attitude toward these drugs, traditionally reserved for patients with repeated non-adherence to treatment.

Original languageEnglish
Pages (from-to)168-193
Number of pages26
JournalItalian Journal of Psychopathology
Volume21
Issue number2
Publication statusPublished - Jun 1 2015

Fingerprint

Schizophrenia
Antipsychotic Agents
Pharmacogenetics
Therapeutics
Pharmaceutical Preparations
Play Therapy
Community Mental Health Services
Patient Preference
Cognitive Therapy
Hospitalization
Clinical Trials
Pharmacology
Recurrence
Injections

Keywords

  • Pharmacological treatment
  • Rehabilitative and psychosocial psychotherapy

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Altamura, A. C., Fagiolini, A., Galderisi, S., Rocca, P., & Rossi, A. (2015). Integrated treatment of schizophrenia. Italian Journal of Psychopathology, 21(2), 168-193.

Integrated treatment of schizophrenia. / Altamura, A. C.; Fagiolini, A.; Galderisi, S.; Rocca, P.; Rossi, A.

In: Italian Journal of Psychopathology, Vol. 21, No. 2, 01.06.2015, p. 168-193.

Research output: Contribution to journalArticle

Altamura, AC, Fagiolini, A, Galderisi, S, Rocca, P & Rossi, A 2015, 'Integrated treatment of schizophrenia', Italian Journal of Psychopathology, vol. 21, no. 2, pp. 168-193.
Altamura AC, Fagiolini A, Galderisi S, Rocca P, Rossi A. Integrated treatment of schizophrenia. Italian Journal of Psychopathology. 2015 Jun 1;21(2):168-193.
Altamura, A. C. ; Fagiolini, A. ; Galderisi, S. ; Rocca, P. ; Rossi, A. / Integrated treatment of schizophrenia. In: Italian Journal of Psychopathology. 2015 ; Vol. 21, No. 2. pp. 168-193.
@article{e0b683e1ac5f4a3bb4c65d809f36c45b,
title = "Integrated treatment of schizophrenia",
abstract = "Psychosocial therapies play an important role in the treatment of schizophrenia. These therapies are aimed at improving the functioning of the patient in the community, which in turn can lead to clinical improvement, such as reduction in the number of relapses or hospitalizations. Substantial evidence supports the use of many psychosocial therapies in schizophrenia, including cognitive behavioral therapy, assertive community treatment, cognitive remediation and functional skills training. The customization of pharmacological therapy in schizophrenia, besides the experience of the clinician and individual preferences of the patient, should be based on three sets of objective data: 1) clinical predictors of response to therapy; 2) predictable side effects of therapy; 3) pharmacogenetic and pharmacogenomic data. It has been made a considerable effort to improve adherence to antipsychotic treatment through the development of drugs with better tolerability, in formulations that enable long-term administration of the drug, including injectable long-acting (depot) antipsychotics. In recent years the development of these formulations of atypical antipsychotics and the promising results obtained in clinical trials are changing the attitude toward these drugs, traditionally reserved for patients with repeated non-adherence to treatment.",
keywords = "Pharmacological treatment, Rehabilitative and psychosocial psychotherapy",
author = "Altamura, {A. C.} and A. Fagiolini and S. Galderisi and P. Rocca and A. Rossi",
year = "2015",
month = "6",
day = "1",
language = "English",
volume = "21",
pages = "168--193",
journal = "Giornale Italiano di Psicopatologia",
issn = "1592-1107",
publisher = "Pacini Editore s.r.l.",
number = "2",

}

TY - JOUR

T1 - Integrated treatment of schizophrenia

AU - Altamura, A. C.

AU - Fagiolini, A.

AU - Galderisi, S.

AU - Rocca, P.

AU - Rossi, A.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Psychosocial therapies play an important role in the treatment of schizophrenia. These therapies are aimed at improving the functioning of the patient in the community, which in turn can lead to clinical improvement, such as reduction in the number of relapses or hospitalizations. Substantial evidence supports the use of many psychosocial therapies in schizophrenia, including cognitive behavioral therapy, assertive community treatment, cognitive remediation and functional skills training. The customization of pharmacological therapy in schizophrenia, besides the experience of the clinician and individual preferences of the patient, should be based on three sets of objective data: 1) clinical predictors of response to therapy; 2) predictable side effects of therapy; 3) pharmacogenetic and pharmacogenomic data. It has been made a considerable effort to improve adherence to antipsychotic treatment through the development of drugs with better tolerability, in formulations that enable long-term administration of the drug, including injectable long-acting (depot) antipsychotics. In recent years the development of these formulations of atypical antipsychotics and the promising results obtained in clinical trials are changing the attitude toward these drugs, traditionally reserved for patients with repeated non-adherence to treatment.

AB - Psychosocial therapies play an important role in the treatment of schizophrenia. These therapies are aimed at improving the functioning of the patient in the community, which in turn can lead to clinical improvement, such as reduction in the number of relapses or hospitalizations. Substantial evidence supports the use of many psychosocial therapies in schizophrenia, including cognitive behavioral therapy, assertive community treatment, cognitive remediation and functional skills training. The customization of pharmacological therapy in schizophrenia, besides the experience of the clinician and individual preferences of the patient, should be based on three sets of objective data: 1) clinical predictors of response to therapy; 2) predictable side effects of therapy; 3) pharmacogenetic and pharmacogenomic data. It has been made a considerable effort to improve adherence to antipsychotic treatment through the development of drugs with better tolerability, in formulations that enable long-term administration of the drug, including injectable long-acting (depot) antipsychotics. In recent years the development of these formulations of atypical antipsychotics and the promising results obtained in clinical trials are changing the attitude toward these drugs, traditionally reserved for patients with repeated non-adherence to treatment.

KW - Pharmacological treatment

KW - Rehabilitative and psychosocial psychotherapy

UR - http://www.scopus.com/inward/record.url?scp=84946038668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946038668&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84946038668

VL - 21

SP - 168

EP - 193

JO - Giornale Italiano di Psicopatologia

JF - Giornale Italiano di Psicopatologia

SN - 1592-1107

IS - 2

ER -